newsfilter
← Latest News
Business Wire·

SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerging Diseases

SAB Biotherapeutics (SAB) has entered into a definitive merger agreement with Big Cypress Acquisition Corp. (NASDAQ:BCYP) and upon closing, the combined company is expected to be listed on NASDAQ Anticipated resources post-transaction will be used